Fastfutureforward by Christine Weiss

CAR T was designed to fight blood cancer. It just reset three autoimmune diseases at once.

The first-order story is the patient getting her life back. The next story is what happens to the entire chronic disease management model -- the drugs, the protocols, the economics -- when treatment-free outcomes become reproducible.

If a single infusion can resolve conditions that previously required lifelong disease management, what happens to the chronic illness treatment model entirely? What does this mean for how employers think about long-term health benefits? For how insurers price lifetime risk? For the pharmaceutical pipelines built on ongoing prescriptions?

Read the full story on SingularityHub, link in comments.

BYE-BYE POWERPOINT 👋

CLAUDE can now create a presentation in 2 minutes.

Use these prompts instead and see the magic 👇👇